Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Provided By GlobeNewswire
Last update: May 21, 2025
PARIS and CAMBRIDGE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first quarter of 2025.
Read more at globenewswire.comNASDAQ:NBTX (6/9/2025, 4:30:01 PM)
4.6759
-0.03 (-0.72%)
Find more stocks in the Stock Screener
